The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...

Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related deaths worldwide.

While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a ...

Karnataka: Shilpa Biologicals Pvt Ltd., a fully owned subsidiary of Shilpa Medicare Limited has signed an exclusive ...

The novel therapy is anticipated to function like PD-1/PD-L1 blockade with significant clinical efficacy results in ...

AbTree Biologics AG has signed an exclusive co-development and commercialization partnership with Shilpa Biologicals Pvt Ltd.

Shilpa Medicare soared 10.46% to Rs 696.15 after the company's wholly owned subsidiary, Shilpa Biologicals, inked a strategic partnership with Switzerland-based mAbTree Biologics AG to co-develop and ...

MGNX earnings call for the period ending December 31, 2024. MacroGenics ( MGNX -2.75%) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

Lung cancer remains one of the most widespread and deadliest malignant tumors globally, with a particularly high mortality rate among all cancers. Recently, immunotherapy, particularly immune ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive ...

Clinical characteristics were associated with different survival outcomes in patients treated with immune checkpoint ...